New strategies for cancer immunotherapy: targeting regulatory T cells

The immunosuppressive action of regulatory T (T(reg)) cells is one mechanism attributed to the limited success of cancer immunotherapies with checkpoint blockers. Two recent studies report distinct transcriptional profiles of tumor-infiltrating T(reg) cells and expression of specific molecules, sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Finotello, Francesca, Trajanoski, Zlatko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5273791/
https://www.ncbi.nlm.nih.gov/pubmed/28129791
http://dx.doi.org/10.1186/s13073-017-0402-8
_version_ 1782501782041133056
author Finotello, Francesca
Trajanoski, Zlatko
author_facet Finotello, Francesca
Trajanoski, Zlatko
author_sort Finotello, Francesca
collection PubMed
description The immunosuppressive action of regulatory T (T(reg)) cells is one mechanism attributed to the limited success of cancer immunotherapies with checkpoint blockers. Two recent studies report distinct transcriptional profiles of tumor-infiltrating T(reg) cells and expression of specific molecules, suggesting novel strategies to overcome resistance to cancer immunotherapy.
format Online
Article
Text
id pubmed-5273791
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52737912017-02-01 New strategies for cancer immunotherapy: targeting regulatory T cells Finotello, Francesca Trajanoski, Zlatko Genome Med Research Highlight The immunosuppressive action of regulatory T (T(reg)) cells is one mechanism attributed to the limited success of cancer immunotherapies with checkpoint blockers. Two recent studies report distinct transcriptional profiles of tumor-infiltrating T(reg) cells and expression of specific molecules, suggesting novel strategies to overcome resistance to cancer immunotherapy. BioMed Central 2017-01-27 /pmc/articles/PMC5273791/ /pubmed/28129791 http://dx.doi.org/10.1186/s13073-017-0402-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Finotello, Francesca
Trajanoski, Zlatko
New strategies for cancer immunotherapy: targeting regulatory T cells
title New strategies for cancer immunotherapy: targeting regulatory T cells
title_full New strategies for cancer immunotherapy: targeting regulatory T cells
title_fullStr New strategies for cancer immunotherapy: targeting regulatory T cells
title_full_unstemmed New strategies for cancer immunotherapy: targeting regulatory T cells
title_short New strategies for cancer immunotherapy: targeting regulatory T cells
title_sort new strategies for cancer immunotherapy: targeting regulatory t cells
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5273791/
https://www.ncbi.nlm.nih.gov/pubmed/28129791
http://dx.doi.org/10.1186/s13073-017-0402-8
work_keys_str_mv AT finotellofrancesca newstrategiesforcancerimmunotherapytargetingregulatorytcells
AT trajanoskizlatko newstrategiesforcancerimmunotherapytargetingregulatorytcells

Ejemplares similares